Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DSM 265

Next Previous
X
Search
Drug Profile

DSM 265

Alternative Names: DSM-265; PfSPZ

Latest Information Update: 19 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Monash University; University of Texas Southwestern Medical Center; University of Washington
  • Developer Center for Infectious Disease Research; Fred Hutchinson Cancer Research Center; Medicines for Malaria Venture; Takeda; United States Department of Defense
  • Class Antimalarials; Pyrimidines; Small molecules; Triazoles
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Malaria

Most Recent Events

  • 15 Dec 2022 National Institute of Allergy and Infectious Diseases plans a phase I trial for Malaria (Prevention) in Mali (IV) (NCT05652504)
  • 28 Sep 2021 Discontinued - Phase-I/II for Malaria (In adults, In volunteers, Combination therapy) in Australia (PO)
  • 28 Sep 2021 Discontinued - Phase-II for Malaria (In adults) in Peru (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top